This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.
Is Amneal Pharmaceuticals (AMRX) a Suitable Pick for Value Investors?
by Zacks Equity Research
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
Amneal Pharmaceuticals (AMRX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 5.00% and -3.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Amneal (AMRX)
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
by Zacks Equity Research
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 38.89% and 1.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
AMRX or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 11.11% and -2.81%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 7.69% and 1.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Amneal Pharmaceuticals (AMRX) Might Surprise This Earnings Season
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AMRX or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. CORT: Which Stock Is the Better Value Option?
Can Amneal (AMRX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AMRX or PCRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. PCRX: Which Stock Is the Better Value Option?
Is Amneal Pharmaceuticals (AMRX) a Good Stock to Pick Now?
by Zacks Equity Research
Is Amneal Pharmaceuticals (AMRX) a great pick from the value investor's perspective right now? Read on to know more.
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amneal (AMRX) delivered earnings and revenue surprises of 23.08% and 8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Amneal (AMRX) Ahead of Earnings?
by Zacks Equity Research
Amneal (AMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amneal Pharmaceuticals (AMRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Pharmaceuticals (AMRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) closed at $4.36 in the latest trading session, marking a -1.13% move from the prior day.
Why Amneal (AMRX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate
by Zacks Equity Research
Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.